X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Detection of High-Risk Patients By Aortic Stability Testing

Content Team by Content Team
17th January 2023
in Drug Development, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to a recent study conducted in collaboration by the University of Eastern Finland and Kuopio University Hospital, patients with ascending aortic dilatation are more likely to experience pathological changes in the aortic wall when wall shear stress values derived from magnetic resonance imaging are high. In the future, high-risk patients may be identified using the data. The research is available for free in Frontiers in Physiology.

In ascending aortic dilatation, an aneurysm develops as the aorta gradually enlarges as a result of the weakened aortic wall structure. Serious consequences like aortic dissection or rupture may result from this. The bicuspid aortic valve and a few hereditary disorders are the primary risk factors for ascending aortic dilatation. There is no treatment outside surgery that is successful. Patients are usually asymptomatic, and an aneurysm is only accidentally detected or found after a life-threatening consequence. Following diagnosis, computed tomography or magnetic resonance imaging is used to periodically check the aortic dilatation.

Aorta vascular flow has also been implicated in causing alterations in the aortic wall structure and accelerating the course of disease, in addition to genetics. In patients with ascending aortic dilatation, the new study conducted at the University of Eastern Finland and Kuopio University Hospital demonstrates for the first time the relationship between wall shear stress, aortic wall strength, as well as site-specific cell composition. The findings show that changing wall shear stress in patients controls aortic degeneration, biomechanical features, and cell-driven mechanisms. The work reveals MYH10 as a novel molecular marker for pathogenic alterations in the aortic wall. Future high-risk patient detection efforts may make use of these findings.

Academy Research Fellow of the University of Eastern Finland, Johanna Laakkonen, states that the goal of her study is to find novel molecular pathways for aortic dilatation that might be used to create treatments and diagnostics for the condition. According to Professor Marja Hedman of the University of Eastern Finland and Kuopio University Hospital, they aim to find individuals with a high risk of aortic dilatation or burst and improve the follow-up of these patients, thereby minimising the risk for life-threatening complications.

Previous Post

The FDA Has Finalized Its Prescription Drug REMS Guidelines

Next Post

Addressing The Antibiotic Shortage Challenge Across Europe

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Addressing The Antibiotic Shortage Challenge Across Europe

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In